Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesEfficacy and safety of fixed-dose loratadine/montelukast in seasonal allergic rhinitis: Effects on nasal congestion
Allergy and Asthma Proceedings, 06/30/09
Prenner B et al. - Nasal decongestant activity of L/M was significantly higher than that of placebo and similar to that of PSE in symptomatic AR subjects. L/M showed a safety profile similar to placebo and was better tolerated than PSE. Thus, L/M offers a safe and efficacious alternative to PSE for the treatment of nasal congestion associated with AR.
Related Articles
Time Interval and the Factors Associated with the Development of Asthma in Patients with Allergic Rhinitis
Lung, 10/09/09
Relevance Score: 91%
Nonallergic Rhinitis Symptoms More Severe Than Allergic Rhinitis
ScienceDaily, 10/06/09
Relevance Score: 89%
Evidence for the involvement of free light chain immunoglobulins in allergic and nonallergic rhinitis
Journal of Allergy and Clinical Immunology, 10/12/09
Relevance Score: 88%
Botox Sponge Replaces Needles for Rhinitis Patients
Ivanhoe, 10/19/09
Relevance Score: 87%
No Need For Needles: Botox Sponge Treats Intrinsic Rhinitis
ScienceDaily, 10/16/09
Relevance Score: 87%
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial
BMC Infectious Diseases, 12/03/09
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial
Amyotrophic Lateral Sclerosis, 12/03/09
Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09
Sponsor
Article Search
Sponsor